← Leaderboards
Karen M Cichowski
Brigham And Women'S Hospital
$14,585,944
Attributed
$15,289,185
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,289,185 · 8
By mechanism
R01$11,915,689 · 4
U01$3,327,696 · 2
R13$45,800 · 2
Top collaborators
- Brigitte Widemann4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- David J. Kwiatkowski$31,996,627
- Elizabeth P Henske$25,563,270
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorSignal TransductionMalignant NeoplasmsInsightPathway InteractionsSyndromeHereditary Malignant NeoplasmClinical TrialsMutationProteinsIn VitroIn VivoPlayNeurofibromatosis 1ComplexEffective TherapyMediatingBiochemicalRas Gtpase-Activating ProteinsResistanceCombined Modality TherapyPreclinical StudyResponseCells
Grant awards (45)
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors$539,600
U01 · FY2025 · CA · contact PI
Developing new therapeutic strategies for distinct Ras-driven cancers$478,002
R01 · FY2025 · CA · contact PI
Developing new therapeutic strategies for distinct Ras-driven cancers$454,102
R01 · FY2024 · CA · contact PI
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors$334,967
U01 · FY2024 · CA · contact PI
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors$565,936
U01 · FY2023 · CA · contact PI
Developing new therapeutic strategies for distinct Ras-driven cancers$483,547
R01 · FY2023 · CA · contact PI
Preclinical-Clinical Trials Collaboration to effectively advance new combination therapies for malignant peripheral nerve sheath tumors$480,710
U01 · FY2022 · CA · contact PI
Developing new therapeutic strategies for distinct Ras-driven cancers$475,403
R01 · FY2022 · CA · contact PI
Developing new therapeutic strategies for distinct Ras-driven cancers$485,105
R01 · FY2021 · CA · contact PI
Co-targeting oncogenic pathways in advanced prostate cancer$381,212
R01 · FY2020 · CA · contact PI
Elucidating the Regulation and Function of the NF1 tumor suppressor$316,635
R01 · FY2020 · CA · contact PI
Co-targeting oncogenic pathways in advanced prostate cancer$369,775
R01 · FY2019 · CA · contact PI
Elucidating the Regulation and Function of the NF1 tumor suppressor$307,135
R01 · FY2019 · CA · contact PI
Developing a translational pipeline for NF1-mutant malignancies$212,444
U01 · FY2019 · CA · contact PI
Co-targeting oncogenic pathways in advanced prostate cancer$381,212
R01 · FY2018 · CA · contact PI
Elucidating the role of new RasGAP tumor suppressors in cancer$332,291
R01 · FY2018 · CA · contact PI
Elucidating the Regulation and Function of the NF1 tumor suppressor$316,635
R01 · FY2018 · CA · contact PI
Developing a translational pipeline for NF1-mutant malignancies$235,046
U01 · FY2018 · CA · contact PI
Co-targeting oncogenic pathways in advanced prostate cancer$381,212
R01 · FY2017 · CA · contact PI
Developing a translational pipeline for NF1-mutant malignancies$380,076
U01 · FY2017 · CA · contact PI
Elucidating the role of new RasGAP tumor suppressors in cancer$332,291
R01 · FY2017 · CA · contact PI
Elucidating the Regulation and Function of the NF1 tumor suppressor$316,635
R01 · FY2017 · CA · contact PI
Developing a translational pipeline for NF1-mutant malignancies$578,917
U01 · FY2016 · CA · contact PI
Co-targeting oncogenic pathways in advanced prostate cancer$381,212
R01 · FY2016 · CA · contact PI
Elucidating the role of new RasGAP tumor suppressors in cancer$332,291
R01 · FY2016 · CA · contact PI
Elucidating the Regulation and Function of the NF1 tumor suppressor$316,635
R01 · FY2016 · CA · contact PI
Elucidating the role of new RasGAP tumor suppressors in cancer$332,224
R01 · FY2015 · CA · contact PI
Elucidating the role of new RasGAP tumor suppressors in cancer$331,419
R01 · FY2014 · CA · contact PI
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in$276,167
R01 · FY2014 · CA · contact PI
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in$267,627
R01 · FY2013 · CA · contact PI
FASEB SRC on Regulation and Function of Small GTPases$4,000
R13 · FY2013 · CA · contact PI
Elucidating the Function of the NF1 Tumor Suppressor and its Effector Pathways in$284,709
R01 · FY2012 · CA · contact PI
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis$318,505
R01 · FY2011 · CA · contact PI
Elucidating the Function of the NF1 tumor suppressor and its effector pathways in$284,401
R01 · FY2011 · CA · contact PI
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis$324,210
R01 · FY2010 · CA · contact PI
Elucidating the Function of the NF1 tumor suppressor and its effector pathways in$292,751
R01 · FY2010 · CA · contact PI
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis$321,811
R01 · FY2009 · CA · contact PI
Dynamic Regulation of Ras via the NF1 tumor Suppressor$286,105
R01 · FY2009 · CA · contact PI
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis$300,291
R01 · FY2008 · CA · contact PI
Dynamic Regulation of Ras via the NF1 tumor Suppressor$280,637
R01 · FY2008 · CA · contact PI
Elucidating the role of the mTOR pathway in NF1-related tumorigenesis$302,105
R01 · FY2007 · CA · contact PI
Dynamic Regulation of Ras via the NF1 tumor Suppressor$280,637
R01 · FY2007 · CA · contact PI
2007 Neurofibromatosis Conference$41,800
R13 · FY2007 · NS · contact PI
Dynamic Regulation of Ras via the NF1 tumor Suppressor$289,019
R01 · FY2006 · CA · contact PI
Dynamic Regulation of Ras via the NF1 tumor Suppressor$301,741
R01 · FY2005 · CA